216 related articles for article (PubMed ID: 20724574)
1. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.
Heinemann V; Di Gioia D; Vehling-Kaiser U; Harich HD; Heinrich B; Welt A; Ziske C; Deutsch G; Pihusch R; Kölbl H; Hegewisch-Becker S; Michl M; Stemmler HJ
Ann Oncol; 2011 Mar; 22(3):603-608. PubMed ID: 20724574
[TBL] [Abstract][Full Text] [Related]
2. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
[TBL] [Abstract][Full Text] [Related]
4. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
Jahanzeb M; Mortimer JE; Yunus F; Irwin DH; Speyer J; Koletsky AJ; Klein P; Sabir T; Kronish L
Oncologist; 2002; 7(5):410-7. PubMed ID: 12401903
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
Schilling G; Bruweleit M; Harbeck N; Thomssen C; Becker K; Hoffmann R; Villena C; Schütte M; Hossfeld DK; Bokemeyer C; de Wit M
Invest New Drugs; 2009 Apr; 27(2):166-72. PubMed ID: 18696011
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
12. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Burstein HJ; Kuter I; Campos SM; Gelman RS; Tribou L; Parker LM; Manola J; Younger J; Matulonis U; Bunnell CA; Partridge AH; Richardson PG; Clarke K; Shulman LN; Winer EP
J Clin Oncol; 2001 May; 19(10):2722-30. PubMed ID: 11352965
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
Andersson M; Lidbrink E; Bjerre K; Wist E; Enevoldsen K; Jensen AB; Karlsson P; Tange UB; Sørensen PG; Møller S; Bergh J; Langkjer ST
J Clin Oncol; 2011 Jan; 29(3):264-71. PubMed ID: 21149659
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L;
Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer].
Zhou NN; Liu DG; Teng XY; Jiang WQ
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1707-9. PubMed ID: 18819904
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
[TBL] [Abstract][Full Text] [Related]
17. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Livingston RB; Barlow WE; Kash JJ; Albain KS; Gralow JR; Lew DL; Flaherty LE; Royce ME; Hortobagyi GN
Breast Cancer Res Treat; 2011 Nov; 130(1):123-31. PubMed ID: 21826527
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
Lin NU; Seah DS; Gelman R; Desantis S; Mayer EL; Isakoff S; Dipiro P; Krop IE; Come SE; Weckstein D; Winer EP; Burstein HJ
Breast Cancer Res Treat; 2013 Jun; 139(2):403-10. PubMed ID: 23645007
[TBL] [Abstract][Full Text] [Related]
20. Combination of trastuzumab and vinorelbine in metastatic breast cancer.
Suzuki Y; Tokuda Y; Saito Y; Ohta M; Tajima T
Jpn J Clin Oncol; 2003 Oct; 33(10):514-7. PubMed ID: 14623919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
